Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a 1-for-3 reverse stock split of its common stock, effective September 8, 2021. This decision follows approval from a majority of shareholders at a special meeting held in December 2020. The reverse split aims to align Jaguar's stock price with institutional investing standards, enhancing its appeal to long-term investors. Post-split, every three shares will convert to one, and fractional shares will be compensated with cash. Jaguar continues its focus on developing plant-based non-opioid medicines for gastrointestinal issues.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the voting results from its Annual Meeting of Stockholders held on September 3, 2021. Proposals 1, 2, 4, 5, and 6 were approved, including the election of a director and the ratification of the accounting firm. However, Proposal 3 to increase authorized common stock from 150 million to 290 million shares failed to pass, despite over 75% of votes in favor. The stockholders chose to hold advisory votes on executive compensation every three years. More details are available in the proxy statement filed with the SEC.
Jaguar Health announced its subsidiary, Napo Pharmaceuticals, submitted an abstract for a clinical study on the effects of crofelemer (Mytesi) on the gut microbiome in HIV/AIDS patients for IDWeek 2021.
The study investigates how crofelemer impacts microbiota in people living with HIV/AIDS undergoing antiretroviral therapy. Mytesi is FDA-approved for treating noninfectious diarrhea in these patients. The findings could provide insights into gut health and inflammation related to HIV.
Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), signed a license agreement with its Italian subsidiary, Napo EU S.p.A., for the development and commercialization of crofelemer and lechlemer in Europe. Napo will receive an upfront payment of $10 million and potential milestone payments. The initial focus is on securing accelerated conditional approval for short bowel syndrome with intestinal failure. Napo EU also plans to explore further indications, contingent on additional payments and funding.
Jaguar Health's subsidiary, Napo Pharmaceuticals, announced the completion of a preclinical toxicology study for lechlemer (NP-300), targeting diarrhea relief from cholera and other infections. Supported by the National Institute of Allergy and Infectious Diseases, this study is crucial for filing an Investigational New Drug (IND) application in early 2022. Lechlemer is derived from Croton lechleri and aims to provide cost-effective treatment, particularly for neglected diseases. The company continues to conduct additional necessary studies for the IND application.
Jaguar Health reported second quarter 2021 results with Mytesi net revenue of approximately $0.4 million, marking an 88% decline from $3.2 million in Q2 2020. Gross revenue for Mytesi fell 22% to $4.9 million compared to $6.3 million in the same quarter last year. The company is shifting to direct sales through specialty pharmacies, which aims to lower distribution costs and enhance patient access. Increased R&D expenses of $3.9 million illustrate ongoing clinical trial commitments. The net loss for the quarter was $14.1 million, worsening from $9.2 million in Q2 2020.
Jaguar Health (NASDAQ:JAGX) has announced a time change for its upcoming investor webcast on August 13, 2021, now scheduled for 8:00 AM Eastern Time.
The company focuses on developing plant-based medications aimed at treating gastrointestinal issues, particularly chronic diarrhea in patients with HIV/AIDS. Their product, Mytesi, is FDA approved for this purpose.
Jaguar will file its Q2 2021 10-Q on the same day as the webcast.
Jaguar Health (NASDAQ:JAGX) announced an investor webcast scheduled for August 13, 2021, at 8:30 AM ET to discuss Q2 financials and company updates. Additionally, in recognition of African Traditional Medicine Day on August 31st, Jaguar is launching an educational awareness contest to honor Indigenous healers. Participants can enter the contest for free, with entries due by 9:00 AM ET on August 31, 2021. The winner will receive a signed painting by Anthony J. Conte. For more details, visit Jaguar's official website.
Jaguar Health (NASDAQ:JAGX) announced the adjournment of its Annual Meeting of Stockholders to September 3, 2021, due to insufficient quorum. Over 75% of votes cast supported proposals 2, 3, 4, and 6. Only an additional 0.84% of eligible stock needs to vote for quorum to be achieved. The company emphasized the importance of shareholder participation, which has been costly and distracting. Stockholders can vote online or through their brokers. No changes were made to the proposals, and the record date remains April 12, 2021.
Jaguar Health (NASDAQ:JAGX) announced an upcoming investor webcast featuring CEO Lisa Conte on July 29, 2021, at 8:30 AM ET. The event aims to provide updates on Jaguar and its subsidiaries, including Napo Pharmaceuticals and Napo EU S.p.A. The recent financing closure by Dragon SPAC for approximately €8.83 million underscores Jaguar's focus on expanding its plant-based gastrointestinal medicines. The company’s Mytesi product, approved by the U.S. FDA, offers symptomatic relief for adults with HIV/AIDS experiencing noninfectious diarrhea.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
